Quinolinone derivatives as PARP and TANK inhibitors

A compound of formula (I),

• the N-oxide forms, the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein
• m is 0, 1 or 2 and when m is 0 then a direct bond is intended;
• n is 0, 1, 2, 3 or 4 and when n is 0 then a direct bond is intended;
• X is a direct bond, CR10R11, (C═O)NR8, NR8, O or C≡C;
• R1 is aryl or Het;
• wherein aryl is phenyl or naphthalenyl;
• wherein Het is thienyl, pyrrolyl, pyrrolinyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, furanyl, piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, piperazinyl, pyrazinyl, triazinyl, indolizinyl, azaindolizinyl, indolyl, indolinyl, benzothienyl, indazolyl, benzoxazolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzotriazolyl, chromanyl, purinyl, quinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxazolinyl, naphthyridinyl or pteridinyl;
• two carbon atoms on aryl or Het can be bridged thereby forming a bi- or tricyclic moiety with a bivalent radical selected from
• —O—CH2—CH2—O— (a-1),
• —CH2—O—CH2—O— (a-2),
• —O—CH2—CH2—CH2— (a-3),
• —O—CH2—CH2—NR8— (a-4),
• —O—CR82—O— (a-5),
• —O—CH2—CH2— (a-6),
• —CH2—N—CH2—CH2— (a-7),
• —(CH2)3— (a-8), or
• —(CH2)4— (a-9);
• each aryl, Het, bridged aryl or bridged Het can be substituted with one, two, three, four or five substituents each independently selected from hydrogen, halo, cyano, nitro, hydroxycarbonyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, aminoC3-6cycloalkyl, haloC1-6alkyl, trihaloC1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C2-6alkenylcarbonyl, oxime, C1-6alkyloxime, amidoxime, —C≡C—CH2O—CH3, —C≡C—CH2N(CH3)2, —C≡C—Si(CH3)3, hydroxyC1-6alkyl, hydroxyC2-6alkenyl, hydroxyC2-6alkynyl, cyanoC1-6alkyl, cyanoC2-6alkenyl, aminocarbonylC1-6alkyl, C1-6alkylsulfonylC1-6alkyl, C1-6alkylsulfonylC2-6alkenyl, C1-6alkylsulfonylC1-6alkynyl,—PO(OC1-6alkyl)2, —B(OH)2, —S—CH3, SF5, C1-6alkylsulfonyl, —NR8R9, C1-6alkylNR8R9, —OR8, —C1-6alkylOR8, —CONR8R9, piperidinylC1-6alkyl, piperazinylC1-6alkyl, C1-6alkylpiperazinylC1-6alkyl, morpholinylC1-6alkyl, piperidinyl, piperazinyl, C1-6alkylpiperazinyl, morpholinyl, phenyl, thienyl, pyrazolyl, pyrrolyl, pyrrolidinyl, pyridinyl, pyrimidinyl, oxadiazolyl, imidazolyl, imidazolylC2-6alkynyl, C1-6alkylimidazolylC2-6alkynyl, cyanopyridinyl, phenylC1-6alkyl, phenylC2-6alkenyl, morpholinylC1-6alkyl, C1-6alkyloxyphenyl, trihaloC1-6alkylphenyl, methylpyrazolyl, halopyrimidinyl or dimethylaminopyrrolidinyl;
• R2 is hydrogen, methyl, ethyl, propyl, C3-6cycloalkyl, C3-6cycloalkylmethyl, fluor, phenyl, cyanophenyl or trifluoromethyl;
• R3 is methyl, ethyl, propyl, hydroxymethyl, halo, trifluoromethyl, methyloxy or C1-6alkylcarbonyl;
• R4 is hydrogen, halo, methyl, aminocarbonyl, hydroxyaminocarbonyl, NR8R9C1-6alkyl-, cyanomethyl, hydroxymethyl or Het;
• each R5, R6 and R7 is independently selected from hydrogen, halo, C1-6alkyloxy, cyano, C1-6alkyl, —OCH2CH2NR8R9, —CH2OCH2CH2NR8R9, —OCH2CH2CH2NR8R9 or C1-6alkyloxyC1-6alkyloxy;
• each R8 and R9 is independently selected from hydrogen, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbonyl, C1-6alkylsulfonylC1-6alkyl, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, dihydroxyC1-6alkyl, cyanoC1-6alkyl, trihaloC1-6alkyl, phenylC1-6alkyl, (diC1-6alkyl)aminoC1-6alkyl, C1-6alkylsulfonyl, morpholinylC1-6alkyl, morpholinylcarbonyl, piperazinylC1-6alkyl, C1-6alkylpiperazinylC1-6alkyl, piperidinylC1-6alkyl, thiomorpholinylC1-6alkyl, C3-6cycloalkylmethyl, pyridinyl, pyrimidinyl, phenyl, halophenyl, oxanylC1-6alkyl, C1-6alkylsulfonylC1-6alkyl or C1-6alkylcarbonylaminoC1-6alkyl;
• each R10 and R11 is independently selected from hydrogen, methyl, hydroxyl, or taken together with the carbon atom to which they are attached can form a cyclopropyl ring or a radical of formula C(═O).